pyrroles has been researched along with Leukemia, Myeloid, Acute in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.67) | 18.2507 |
| 2000's | 14 (23.33) | 29.6817 |
| 2010's | 33 (55.00) | 24.3611 |
| 2020's | 12 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, S; Carpio, C; Cassier, PA; Chatterjee, M; Chromik, J; de Vos, F; DeAngelo, DJ; Esteve, J; Fabre, C; Ferretti, S; Guerreiro, N; Halilovic, E; Kiladjian, JJ; Lin, CC; Mariconti, L; Meille, C; Minami, H; Mous, R; Pereira, B; Radhakrishnan, R; Steeghs, N; Stein, EM; Suarez, C; Tai, D; Yamamoto, N | 1 |
| Asatiani, E; Berenson, JR; Bordoni, R; Cook, RJ; Edenfield, WJ; Mohan, S; Savona, MR; Srinivas, N; Zeidan, AM; Zhou, G | 1 |
| Chen, S; Cui, B; Hao, Q; Huang, W; Liu, F; Wang, J; Xue, S; Zhang, Y | 1 |
| Bazinet, A; Bhalla, K; Borthakur, G; Curry, JL; Daver, N; Heberton, M; Kadia, T; Khoury, JD; Kim, K; Konopleva, M; Loghavi, S; Miller, D; Pemmaraju, N; Pierce, S; Wilson, NR | 1 |
| Chen, SN; He, XF; Sun, AN; Wang, Q; Wu, DP; Wu, Q; Yang, XF; Yin, J; Zhang, JR; Zhang, ZB; Zhu, F | 1 |
| Alcitepe, İ; Karatekin, İ; Kaymaz, BT; Salcin, H | 1 |
| Abdel-Wahab, O; Arrowsmith, CH; Barbash, O; Barsyte-Lovejoy, D; Bonaldi, T; Delwel, R; Fong, JY; Gay, F; Goy, PA; Guccione, E; Hart, T; Jin, J; Kawabata, KC; Ki, M; Koh, CM; Kotini, AG; Lee, SC; Low, DH; Luciani, GM; Massignani, E; Melnick, A; Minden, MD; Musiani, D; Mzoughi, S; Papapetrou, EP; Penson, A; Pignata, L; Rialdi, A; Schwarz, M; Shen, Y; Szewczyk, MM; Thompson, C; Wollmann, H; Wouters, BJ; Wun, CM | 1 |
| Cooper, VS; Patel, RK; Shen, K; Smithgall, TE; Snyder, D; Weir, MC | 1 |
| Boerries, M; Dittmann, J; Fulda, S; Haydn, T; Metzger, P; Vogler, M; Ward, GA | 1 |
| Bollag, G; Frankfurt, O; Hsu, HH; Kayser, S; Lam, B; Le, MH; Levis, MJ; Pagel, JM; Perl, AE; Roboz, GJ; Severson, PL; Smith, CC; Stone, RM; Wang, ES; West, BL; Zhang, C | 1 |
| Cichoń, I; Kołaczkowska, E; Mazur, L; Opydo-Chanek, M; Rak, A | 1 |
| Ailiken, G; Haruma, T; Hashimoto, N; Ishida, K; Kawashima, Y; Muraoka, H; Murata, K; Nagano, H; Nakayama, A; Nishimura, M; Ochiiwa, H; Ohara, O; Ohkubo, S; Tanaka, T; Yamagata, K; Yokoyama, M; Yoshimura, C | 1 |
| Bollag, G; Hernandez, D; Hizukuri, Y; Lee, L; Levis, M; Ma, Y; Narahara, M; Powell, B; Rajkhowa, T; Severson, P; Sumi, H; Zhang, C | 1 |
| Albert, DH; Bellin, RJ; Boyiadzis, M; Bui, MH; Cai, T; Cavazos, A; Dorritie, KA; Faivre, EJ; Feng, W; Ferguson, DC; Goodwin, NC; Han, L; Hessler, P; Huang, X; Kati, WM; Konopleva, M; Kuruvilla, VM; Lam, LT; Lin, X; Lu, X; Magoc, TJ; McDaniel, KF; Mehta, G; Plotnik, JP; Rowe, J; Shanmugavelandy, SS; Shen, Y; Uziel, T; Zha, Z; Zhang, L; Zhang, Q | 1 |
| Adachi, S; Bando, T; Hirata, M; Ito, K; Kamikubo, Y; Kaneda, Y; Kashiwazaki, G; Kataoka, T; Kitamura, T; Kiyose, H; Liu, PP; Maeda, R; Maeda, S; Matsuo, A; Matsuo, H; Mitsuda, Y; Morita, K; Muto, M; Naka, K; Noura, M; Okuno, Y; Sugiyama, H; Suzuki, K; Tanaka, S; Taniguchi, J; Tokumasu, M; Tokushige, C; Yamada, Y; Yano, A | 1 |
| Gray, NS; Hellwig, S; Liu, Y; Smithgall, TE; Tan, L; Weir, MC | 1 |
| Honma, T; Kikuzato, K; Koda, Y; Koyama, H; Kukimoto-Niino, M; Mikuni, J; Shirai, F; Shirouzu, M; Tanaka, A; Tomabechi, Y; Yuki, H | 1 |
| Abarrategi, A; Blackwood, E; Bonnet, D; Di Tullio, A; Grey, W; Gribben, J; Mian, S; Rouault-Pierre, K; Stewart, A | 1 |
| Advani, AS; Biddle-Snead, C; Bixby, D; DeAngelo, DJ; Erba, HP; Faderl, S; Fathi, AT; Ho, PA; Jillella, AP; Kovacsovics, T; Lancet, JE; O'Meara, MM; Ravandi, F; Stein, AS; Stein, EM; Walter, RB; Zhao, B | 1 |
| Katayama, K; Noguchi, K; Sugimoto, Y; Takami, M | 1 |
| Advani, AS; Bixby, D; DeAngelo, DJ; Erba, HP; Faderl, S; Fathi, AT; Ho, PA; Jillella, A; Kovacsovics, TJ; Lancet, JE; Levy, MY; O'Meara, MM; Ravandi, F; Stein, AS; Stein, EM; Voellinger, J; Walter, RB | 1 |
| Aoki, Y; Fukami, T; Goto, T; Handa, N; Hashizume, Y; Honma, T; Ishikawa, F; Kajita, H; Kaneko, A; Kuratani, M; Mikuni, J; Najima, Y; Ogahara, I; Ohara, O; Saito, Y; Shirouzu, M; Shultz, LD; Sone, A; Suzuki, N; Takagi, S; Tanaka, A; Tanaka, S; Taniguchi, S; Tomabechi, Y; Tomizawa-Murasawa, M; Uchida, N; Wakiyama, M; Yokoyama, S; Yuki, H | 1 |
| Baker, SD; Buaboonnam, J; Enemark, EJ; Inaba, H; Mullighan, CG; Neale, GA; Olsen, SR; Orwick, S; Rubnitz, JE; Shurtleff, S; Wang, YD; Zatechka, DS; Zimmerman, EI | 1 |
| Accordi, B; Barozzi, P; Basso, G; Bertacchini, J; Cocco, L; De Pol, A; Forghieri, F; Giordan, M; Guida, M; Liotta, L; Luppi, M; Marmiroli, S; Martelli, AM; Mediani, L; Milani, G; Petricoin, E | 1 |
| Amin, S; Barth, BM; Claxton, D; Doi, K; Gowda, K; Liu, Q; Loughran, TP; Wang, HG | 1 |
| Chen, Y; Chen, Z; Cho, H; Gray, NS; Griffin, JD; Liu, F; Liu, Q; Mitsiades, C; Nelson, E; Nonami, A; Sattler, M; Weisberg, E; Wong, KK; Zhang, J | 1 |
| Borthakur, G; Carter, TH; Claxton, D; DeAngelo, DJ; Erba, H; Goard, C; Raza, A; Schimmer, AD; Tallman, MS | 1 |
| Anizon, F; Bourhis, M; Døskeland, SO; Giraud, F; Herfindal, L; Moreau, P; Nauton, L; Théry, V | 1 |
| Caldwell, JT; Edwards, H; Ge, Y; Taub, JW; Wang, G; Xie, C | 1 |
| Galanis, A; Levis, M | 1 |
| Chandra, J; Corrales-Medina, FF; Manton, CA; Orlowski, RZ | 1 |
| DeRyckere, D; Earp, HS; Frye, S; Graham, DK; Hill, AA; Jordan, CT; Kirkpatrick, G; Lee-Sherick, AB; Liu, J; Menachof, KK; Page, LS; Rinella, S; Stashko, MA; Wang, X; Wei, Q; Zhang, D; Zhang, W | 1 |
| Döhner, H; Döhner, K; Fiedler, W; Ganser, A; Göhring, G; Götze, K; Heuser, M; Janning, M; Kayser, S; Kebenko, M; Krauter, J; Schittenhelm, M; Schlenk, RF; Teleanu, V; Thol, F; Weber, D | 1 |
| Bashir, A; Bollag, G; Burton, EA; Carias, H; Damon, LE; Habets, G; Hsu, HH; Ibrahim, PN; Kasarskis, A; Lasater, EA; Le, MH; Lin, KC; Massi, E; Matusow, B; Pendleton, M; Perl, A; Powell, B; Sebra, R; Shah, NP; Shellooe, R; Smith, CC; Spevak, W; Tsang, G; West, BL; Zhang, C; Zhang, J; Zhang, Y | 1 |
| Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D | 1 |
| Bujak, A; Dymek, B; Dzwonek, K; Grygielewicz, P; Gunerka, P; Lamparska-Przybysz, M; Pietrucha, T; Stanczak, A; Turowski, P; Wieczorek, M | 1 |
| Chandra, J; Keating, MJ; Miller, CP; Palladino, M; Rudra, S; Wierda, WG | 1 |
| Ikezoe, T; Nishioka, C; Yang, J; Yokoyama, A | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Garcia-Manero, G; Hu, Y; Jia, Y; Kadia, T; O'Brien, S; Tong, W; Viallet, J; Wei, Y; Yang, H; Zhang, M | 1 |
| Chen, X; Du, W; He, Y; Huang, S; Li, X; Liu, W; Xiao, H; Yang, L; Zhang, J; Zheng, J | 1 |
| Chabner, BA; Fathi, AT | 1 |
| Bhatt, L; Chang, CJ; Cotter, TG; Dickinson, BC; Gough, DR; Naughton, R; Stanicka, J; Woolley, JF | 1 |
| Hsu, SL; Hwang, GY; Hwang, WL; Liu, HC; Teng, CL; Tsai, JR; Yu, CT | 1 |
| Chen, Y; Fu, X; Guo, Y; Xu, X; Zhao, ZJ | 1 |
| Ashton, JM; Becker, MW; Brookes, PS; Callahan, K; Grose, V; Jordan, CT; Lagadinou, ED; Liesveld, JL; Minhajuddin, M; Neering, SJ; O'Dwyer, KM; Pei, S; Rossi, RM; Sach, A | 1 |
| Albers, C; Duyster, J; Illert, AL; Leischner, H; Peschel, C; Verbeek, M; von Bubnoff, N; Yu, C | 1 |
| Berdel, WE; Brega, NM; Cavalli, F; Duhrsen, U; Fiedler, W; Flasshove, M; Hossfeld, DK; Jacobs, M; Jung, W; Kuse, R; Loges, S; Mesters, R; O'Farrell, AM; Ottmann, OG; Scigalla, P; Serve, H; Staib, P; Thomalla, J; Tinnefeld, H | 1 |
| Bello, C; Berdel, WE; Cherrington, JM; Cooper, MA; Fiedler, W; Foran, JM; Heinrich, MC; Jacobs, M; Kelsey, S; Kim, H; Louie, SG; Manning, WC; Nicholas, S; O'Farrell, AM; Paquette, RL; Scigalla, P; Serve, H; Yuen, HA | 1 |
| Voutsadakis, IA | 1 |
| Allred, R; Bello, CL; Berdel, WE; Brega, NM; Cherrington, JM; Döhner, H; Fiedler, W; Hong, W; Hossfeld, DK; Louie, SG; Manning, WC; Massimini, G; O'Farrell, AM; Ottmann, OG; Schwittay, M; Scigalla, P; Serve, H | 1 |
| Berdel, WE; Müller-Tidow, C; Serve, H; Tickenbrock, L | 1 |
| Chow, LQ; Eckhardt, SG | 1 |
| Bortul, R; Evangelisti, C; Grafone, T; Martelli, AM; Martinelli, G; McCubrey, JA; Papa, V; Tabellini, G; Tazzari, PL | 1 |
| Grosicka, A; Grosicki, S; Hołowiecki, J | 1 |
| Duyster, J; Grundler, R; Kancha, RK; Peschel, C | 1 |
| Ikezoe, T; Koeffler, HP; Komatsu, N; Nishioka, C; Takeshita, A; Taniguchi, A; Togitani, K; Yang, J; Yokoyama, A | 1 |
| Ehninger, G; Illmer, T | 1 |
| Baker, SD; Dahl, GV; Hu, S; Inaba, H; Minkin, P; Niu, H; Orwick, S; Rubnitz, J; Shimada, A | 1 |
| Deguchi, K; Kobayashi, K; Nishikawa, M; Omay, SB; Shirakawa, S; Toyoda, H | 1 |
6 review(s) available for pyrroles and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib | 2015 |
Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
Topics: Adult; Animals; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mice; Middle Aged; Prognosis; Proto-Oncogene Proteins; Pyrroles; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2003 |
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Topics: Animals; Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Staurosporine | 2006 |
Sunitinib: from rational design to clinical efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Design; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2007 |
[Clinical importance of angiogenesis and angiogenic factors in oncohematology].
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Hematologic Neoplasms; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neovascularization, Pathologic; Oxindoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propionates; Pyrroles; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors | 2007 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
10 trial(s) available for pyrroles and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Topics: Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Neoplasms; Pyrimidines; Pyrroles; Tumor Suppressor Protein p53 | 2022 |
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Topics: Acetonitriles; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hematologic Neoplasms; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Pyrimidines; Pyrroles | 2022 |
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.
Topics: Aminopyridines; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles | 2020 |
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Benzodiazepines; Female; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Pyrroles; Sialic Acid Binding Ig-like Lectin 3 | 2018 |
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzodiazepines; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Pyrroles; Sialic Acid Binding Ig-like Lectin 3; Survival Rate | 2018 |
A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Blast Crisis; Demography; Drug Administration Schedule; Female; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Neutrophils; Platelet Count; Pyrroles; Treatment Outcome | 2014 |
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyrroles; Remission Induction; Sunitinib; Treatment Outcome | 2015 |
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Cell Separation; Enzyme Inhibitors; Female; Flow Cytometry; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Microcirculation; Middle Aged; Mutation; Polymerase Chain Reaction; Pyrroles; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2003 |
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Topics: Administration, Oral; Adult; Aged; Blast Crisis; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Genotype; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2003 |
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Topics: Aged; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Genotype; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Mutation; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2005 |
44 other study(ies) available for pyrroles and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazoles; Pyrroles; Recurrence; Retrospective Studies; Triazines | 2022 |
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.
Topics: Azacitidine; Humans; Leukemia; Leukemia, Myeloid, Acute; Oxazoles; Pyridines; Pyrroles; Skin Neoplasms | 2022 |
Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation.
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Triazines | 2022 |
HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Oxazoles; Pyridines; Pyrroles; Vorinostat | 2022 |
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
Topics: Animals; Antineoplastic Agents; Catalysis; Enzyme Inhibitors; Ethylenediamines; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; K562 Cells; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Mice, Transgenic; Protein-Arginine N-Methyltransferases; Pyrroles; Repressor Proteins; RNA Splicing; RNA, Neoplasm; THP-1 Cells; Tumor Cells, Cultured; U937 Cells; Xenograft Model Antitumor Assays | 2019 |
Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
Topics: Amino Acid Substitution; Cell Line, Tumor; Drug Resistance, Neoplasm; Exome Sequencing; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Developmental; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mutation, Missense; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-hck; Pyrimidines; Pyrroles; src-Family Kinases | 2019 |
Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
Topics: Aged; Apoptosis; Azacitidine; Baculoviral IAP Repeat-Containing 3 Protein; Cell Line, Tumor; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Morpholines; Piperazines; Pyrroles; Ubiquitin-Protein Ligases | 2020 |
The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; HL-60 Cells; Humans; Indoles; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2020 |
TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia.
Topics: Animals; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Mice; NEDD8 Protein; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrimidines; Pyrroles; RNA-Seq; RNA, Small Interfering; Signal Transduction; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2021 |
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia.
Topics: Animals; Apoptosis; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Oxazoles; Protein Kinase Inhibitors; Pyridines; Pyrroles; Tumor Microenvironment | 2021 |
Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Genetic regulation of the RUNX transcription factor family has antitumor effects.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Core Binding Factor alpha Subunits; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Nylons; Pyrroles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Female; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fes; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Tandem Repeat Sequences | 2017 |
Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.
Topics: Apoptosis; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-hck; Pyrimidines; Pyrroles; Structure-Activity Relationship; Thermodynamics | 2017 |
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Checkpoint Kinase 1; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; U937 Cells; Xenograft Model Antitumor Assays | 2017 |
Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Phosphorylation; Protein Isoforms; Protein Kinase C-alpha; Proto-Oncogene Proteins c-pim-1; Pyrroles; Quinazolines; Serine | 2018 |
A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Bone Marrow Transplantation; Crystallography, X-Ray; Drug Resistance, Neoplasm; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-hck; Pyrimidines; Pyrroles; RNA, Small Interfering; Small Molecule Libraries; Tumor Cells, Cultured; Young Adult | 2013 |
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Topics: Adolescent; Alleles; Animals; Antineoplastic Agents; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Mice; Models, Molecular; Molecular Conformation; Mutation; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Benzothiazoles; Drug Synergism; Feedback, Physiological; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteome; Proto-Oncogene Proteins c-akt; Pyrroles; Retrospective Studies; Signal Transduction; Sunitinib; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Young Adult | 2014 |
Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Bone Marrow Cells; Cell Line, Tumor; Coculture Techniques; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Hematopoietic Stem Cells; Heterografts; Humans; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Pyrroles; RNA Interference; Stromal Cells; Sulfonamides | 2014 |
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.
Topics: Animals; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Genes, ras; Humans; Leukemia, Myeloid, Acute; Mice; Mitogen-Activated Protein Kinase Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Small Molecule Libraries; Up-Regulation | 2014 |
New N-1,N-10-bridged pyrrolo[2,3-a]carbazole-3-carbaldehydes: synthesis and biological activities.
Topics: Antineoplastic Agents; Apoptosis; Carbazoles; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1; Pyrroles | 2014 |
Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.
Topics: Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; DNA Damage; Female; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Pyrroles; U937 Cells | 2015 |
Inhibition of c-Kit by tyrosine kinase inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles | 2015 |
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Hydroxamic Acids; Indoles; Lactones; Leukemia, Myeloid, Acute; Panobinostat; Proteasome Inhibitors; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2015 |
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; c-Mer Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; fms-Like Tyrosine Kinase 3; Granulocyte Precursor Cells; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction; Tumor Cells, Cultured | 2015 |
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; fms-Like Tyrosine Kinase 3; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Models, Molecular; Molecular Conformation; Mutation; Phenylurea Compounds; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Pyrroles; Recurrence; Structure-Activity Relationship | 2015 |
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Topics: bcl-X Protein; Cell Cycle; Cell Line, Tumor; Cyclin D1; Down-Regulation; Gene Expression; Humans; Imidazoles; Janus Kinases; Leukemia, Myeloid, Acute; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyrimidines; Pyrroles; Pyrrolidines; Sulfonamides | 2015 |
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Topics: Acetylation; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Drug Synergism; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunoprecipitation; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxides; Tumor Cells, Cultured; Vorinostat | 2009 |
Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).
Topics: Animals; Antineoplastic Agents; Calcitriol; Cell Differentiation; Drug Synergism; Indoles; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Monocytes; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Vitamins | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
Topics: Apoptosis; Autophagy; Benzamides; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Pyrimidines; Pyrroles; Vorinostat | 2010 |
The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells.
Topics: Apoptosis; Cytarabine; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction | 2010 |
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences | 2011 |
H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.
Topics: Benzoxazoles; Cell Line, Tumor; Endoplasmic Reticulum; Fluorescent Dyes; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hydrogen Peroxide; Imidazoles; Leukemia, Myeloid, Acute; Mitochondria; Mutation; NADPH Oxidases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-pim-1; Pyrroles; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Triazoles | 2012 |
Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Indoles; Leukemia, Myeloid, Acute; Pyrroles; Sunitinib; Treatment Outcome; Tumor Cells, Cultured | 2013 |
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells.
Topics: Cell Growth Processes; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrroles; Signal Transduction | 2012 |
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.
Topics: Apoptosis; Humans; Indoles; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Oxidative Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reactive Oxygen Species; Tumor Cells, Cultured | 2013 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Topics: Antineoplastic Agents; Benzothiazoles; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib | 2013 |
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
Topics: Apoptosis; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Down-Regulation; Etoposide; HL-60 Cells; Humans; Insulin-Like Growth Factor I; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1 | 2007 |
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2007 |
Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase 1; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sunitinib; Tumor Cells, Cultured | 2008 |
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Forskolin potentiates G-CSF-induced proliferation of a murine myeloblastic leukemia cell line.
Topics: Animals; Carbazoles; Cell Division; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Drug Synergism; Enzyme Activation; Granulocyte Colony-Stimulating Factor; Indoles; Interleukin-3; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Mice, Inbred DBA; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 1994 |